AlphAIAlphAI — Financial news for AI agents
timothysykes.comSEP 172 min read$TWST

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

Original reporting
timothysykes.com
Published Sep 17, 2026, 8:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal — source image
Source · timothysykes.com
Decision brief

The 30-second read

$TWSTBullishHigh
01

Why it matters

The collaboration could accelerate Twist's revenue growth and improve margins, reinforcing its high-growth narrative.

02

Market read

New AI partnership drives significant price action in Twist, signaling broader biotech AI trends.

03

What to watch

Potential execution risk and reliance on Lilly's AI roadmap could limit upside.

Relevance 7/10Novelty 8/10Timing: today

Background

Twist Bioscience is a synthetic DNA and sequencing tools provider; the Eli Lilly TuneLab deal expands its role in AI-driven drug discovery.

Company-level read

Ticker impact

$TWSTBullishHigh confidence
Context

Twist Bioscience announced a new collaboration with Eli Lilly's AI drug discovery platform, driving a 9.7% intraday price jump.

Expected impact

Potential for continued short-term rally; watch for volatility on volume spikes.

Evidence & confidence

Deal announced today, large price move, and margin improvement suggest near-term buying pressure.

Market effects

Sector

Highlights growing AI integration in biotech, may lift other synthetic DNA and biotech service stocks.

Regional

Positive for US biotech sector; limited immediate effect outside North America.

Global

Shows cross-industry AI collaborations, relevant to global pharma and tech investors.

Counterpoint

What could challenge this read

The partnership may not translate to revenue quickly; high valuation and cash burn remain concerns.

Key entities

  • company
    Twist Bioscience

    Synthetic DNA and sequencing services provider.

  • company
    Eli Lilly

    Pharmaceutical giant launching AI/ML drug discovery platform TuneLab.

Read at source← All news

Also covered by

4 outlets

Related articles

SEP 17
$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

timothysykes.com3 min
SEP 17
$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

stockstotrade.com3 min
SEP 17
$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.

timothysykes.com2 min
SEP 16
$TWSTMed

Why is Twist Bioscience stock rallying today?

Twist Bioscience (TWST) stock rose 3.7% after joining Eli Lilly's TuneLab platform as a preferred antibody data provider. The deal supports Twist's AI-driven life science strategy, following record Q3 revenue and raised guidance. The stock is near its 52-week high, with NASDAQ and S&P 500 also gaining.

investing.com2 min